Lucas Vitale - Jun 18, 2024 Form 3 Insider Report for Orthofix Medical Inc. (OFIX)

Role: CP&BO
Signature: /s/ J. Andres Cedron, attorney-in-fact
Stock symbol: OFIX
Transactions as of: Jun 18, 2024
Transactions value $: $0
Form type: 3
Date filed: 6/26/2024, 04:30 PM
Previous filing: May 11, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	OFIX	Common Stock						120K	Jun 18, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	OFIX	Employee Stock Option (Right to Buy)							Jun 18, 2024	Common Stock	75.4K	$13.74	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consist of unvested restricted stock units, of which, 10,916 units will vest on March 15, 2025, 10,917 units will vest on March 15, 2026, and 98,254 units will vest on March 15, 2027.
F2	The options shall vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date on which the average closing price of the Company's common stock over a consecutive thirty (30) calendar day period has been equal to or greater than 150% of the exercise price or (ii) with respect to one-third (1/3rd) of the shares of Stock covered hereby on the first anniversary of the Grant Date and one-twelfth (1/12th) of the shares of Stock covered hereby on each of the 15-month, 18-month, 21-month, 24-month, 27-month, 30-month, 33-month and 36-month anniversaries of the Grant Date.

Content

Consist of unvested restricted stock units, of which, 10,916 units will vest on March 15, 2025, 10,917 units will vest on March 15, 2026, and 98,254 units will vest on March 15, 2027.

The options shall vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date on which the average closing price of the Company's common stock over a consecutive thirty (30) calendar day period has been equal to or greater than 150% of the exercise price or (ii) with respect to one-third (1/3rd) of the shares of Stock covered hereby on the first anniversary of the Grant Date and one-twelfth (1/12th) of the shares of Stock covered hereby on each of the 15-month, 18-month, 21-month, 24-month, 27-month, 30-month, 33-month and 36-month anniversaries of the Grant Date.